BioCity Biopharma Unveils Groundbreaking Trial Outcomes for SC0062
BioCity Biopharma (BioCity) has made significant strides in the realm of renal health. Recently, the company presented late-breaking findings from the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ET
Understanding the 2-SUCCEED Clinical Trial
The 2-SUCCEED trial was a comprehensive, multi-center, randomized, double-blind, placebo-controlled Phase II study, involving two distinct cohorts (IgAN and diabetic kidney disease [DKD]). The trial's primary goal for the IgAN cohort was to evaluate SC0062's efficacy, safety, and optimal dosing against a placebo, specifically focusing on its capacity to lower proteinuria in participants at elevated risk of disease progression. Notably, subjects could continue their background therapy with sodium/glucose cotransporter 2 (SGLT2) inhibitors.
A total of 131 participants were randomized into four treatment groups for 24 weeks: either SC0062 at doses of 5 mg, 10 mg, or 20 mg or placebo, administered once daily.
Key Findings from the Study
SC0062 Demonstrated Effective Results in Primary Objective: By week 12, those receiving SC0062 at varying doses (5 mg, 10 mg, 20 mg) exhibited remarkable mean reductions in the 24-hour urine protein-to-creatinine ratio (UPCR): 39.2%, 33.7%, and 48.3% respectively, with the placebo group showing only a 16.5% reduction.
Secondary Endpoints Achieved: For secondary endpoint 1, the percentage of subjects exhibiting a reduction of over 30% in UPCR was significantly higher in the SC0062 groups (48.5%, 62.5%, and 71.0% for 5 mg, 10 mg, and 20 mg respectively) versus 33.3% in the placebo cohort. Additionally, reductions by 40% were noted in 45.5%, 37.5%, and 64.5% of patients in the SC0062 groups compared to just 18.2% in the placebo group. A 50% reduction was achieved in 33.3%, 21.9%, and 51.6% of SC0062 patients versus 12.1% in the placebo group, highlighting the drug's efficacy.
Continued Improvement at Week 24: By week 24, participants on SC0062 exhibited mean UPCR reductions of 39.5%, 46.1%, and 62.3% for the respective doses, compared to a 22.1% reduction in the placebo group.
Subgroup Considerations: Notably, among the subjects, those receiving SGLT2 inhibitors as adjunctive therapy ranged from 46% to 47%. The results remained consistent, indicating SC0062's effectiveness regardless of SGLT2 inhibitor use or prior UPCR levels.
Renal Function Stability: Remarkably, there was no acute decline in estimated glomerular filtration rate (eGFR) over the treatment span, ensuring the safety profile of SC0062 in early treatment phases.
Noteworthy Safety Profile: SC0062 was generally well-accepted by participants, presenting lower rates of side effects like peripheral edema and fluid retention, which are common with other treatments for IgAN. Rates observed were 15% for placebo, tapering down to 6%, 3%, and 3% for SC0062 at increasing doses. Moreover, no significant weight gain or elevation in NT-pro-BNP levels were recorded.
Experiences Shared by Experts
Dr. Hiddo Lambers Heerspink, an esteemed authority on chronic kidney disease (CKD) treatment, highlighted the significant and durable decline in urinary protein excretion linked to SC0062. He supports the initiation of broader, long-term clinical trials involving diverse CKD types, including IgAN, emphasizing that the results advocate strongly for continued investigation into SC0062.
About SC0062
SC0062 distinguishes itself as a groundbreaking ET
About BioCity
Since its establishment in December 2017, BioCity has committed itself to pioneering innovative therapeutics targeted at cancer and autoimmune disorders, including CKD. The firm proudly boasts a diverse pipeline exceeding 10 innovative drug candidates spanning small molecules and advanced hybrid therapies like bispecific antibodies and antibody-drug conjugates (ADCs). Presently, the company is focused on progressing SC0062 through clinical trials, while also advancing various cutting-edge oncology assets aimed at revolutionizing treatment paradigms in cancer care.
Frequently Asked Questions
What is SC0062?
SC0062 is a selective endothelin receptor type A antagonist shown to reduce urinary protein excretion in patients with IgA Nephropathy.
What were the main findings of the 2-SUCCEED trial?
The trial indicated significant reductions in urinary protein levels among those treated with SC0062 compared to a placebo.
How does SC0062 compare to existing treatments for IgAN?
SC0062 has a favorable safety profile and reduced risk of side effects such as fluid retention, unlike many current treatments.
What are the next steps for SC0062?
BioCity plans to initiate larger Phase 3 trials based on the encouraging results from the current study.
Who presented the trial results at ASN?
Dr. Hiddo Lambers Heerspink presented the findings, emphasizing the implications for future CKD treatments.
